Handbook of Clinical medicine

headache, malaise, myalgia, conjunctivitis, eye pain ± photophobia. Complications include pneumonia, exacerbation of chronic lung disease, croup, otitis media, D&V, myositis, encephalitis, Reye syndrome (encephalopathy + fatty degenerative liver failure). Diagnosis: Clinical: acute onset + cough + fever has positive predictive value >79%. Testing limited to outbreaks, and public health surveillance. Includes: viral PCR, rapid antigen testing, viral culture of clinical samples (throat swab, nasal swab, naso- pharyngeal washings, sputum). Treatment: • Uncomplicated infl uenza symptomatic treatment eg paracetamol. Antivirals only if high risk: • Chronic disease: lung, heart, kidney, liver, CNS, DM • Immunosuppression: immunodefi ciency, current or planned or within 6 months of immunosuppressive therapy, CD4 (<200 in adults, <500 if child <5yr) • Pregnancy • >65yr • BMI>40 • <6 months old. • Complicated infl uenza includes lower respiratory tract infection, exacerbation of any underlying medical condition, all needing hospital admission. Give antiviral4 inhibitors of infl uenza neuraminidase: 1 Oseltamivir:P O or NG. Adult dose: 75mg BD. 5d course. 1st line in UK. 2 Zanamivir: inhaled (10mg BD, 5d course, confi rm technique), nebulized, or IV (res- piratory disease aff ecting nebulizer delivery, ITU). Used if: oseltamivir resistance (eg A(H1N1)), poor clinical response to oseltamivir, concerns re
